394 related articles for article (PubMed ID: 9351532)
1. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].
Nemes L; Ceglédi A; Szabó G; Varga M; Sas G
Orv Hetil; 1998 Mar; 139(13):749-52. PubMed ID: 9578703
[TBL] [Abstract][Full Text] [Related]
3. Viral safety of clotting factor concentrates.
Fricke WA; Lamb MA
Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
[TBL] [Abstract][Full Text] [Related]
4. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Pollmann H
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
7. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
[TBL] [Abstract][Full Text] [Related]
10. Concentrate safety and efficacy.
Kasper CK
Haemophilia; 2002 May; 8(3):161-5. PubMed ID: 12010404
[TBL] [Abstract][Full Text] [Related]
11. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
Heimburger N; Karges HE; Weidmann E
Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
14. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
16. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
[No Abstract] [Full Text] [Related]
17. Progress in the clinical management of haemophilia.
Bloom AL
Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
[No Abstract] [Full Text] [Related]
18. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
Habart D
Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
[TBL] [Abstract][Full Text] [Related]
19. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
20. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]